Usefulness of vancomycin treatment individualization via Bayesian algorithms: a 5-year study in critical patients

References

• Póvoa P, Moniz P, Pereira JG, Coelho L. Optimizing antimicrobial drug dosing in critically ill patients. Microorganisms. 2021;9(7):1401. doi:10.3390/microorganisms9071401
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Vazin A, Zand F, Mohammadi-Samani S. Volume of distribution as an early predictor of vancomycin-induced AKI in critically ill patients. Acta Biomed. 2023;94(5):e2023185. doi:10.23750/abm.v94i5.14158
   PubMedGoogle Scholar
• Alnezary FS, Almutairi MS, Gonzales-Luna AJ, Thabit AK. The significance of Bayesian pharmacokinetics in dosing for critically ill patients: a primer for clinicians using vancomycin as an example. Antibiotics (Basel). 2023;12(9):1441. doi:10.3390/antibiotics12091441
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Nation RL. Key challenges in providing effective antibiotic therapy for critically ill patients with bacterial sepsis and septic shock. Clin Pharmacol Ther. 2021;109(4):892–904. doi:10.1002/cpt.2203
   PubMed Web of Science ®Google Scholar
• McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90(2):269–281.
   PubMed Web of Science ®Google Scholar
• Nepal N, Mahara P, Subedi S, et al. Genotypically confirmed vancomycin-resistant Staphylococcus aureus with vanB gene among clinical isolates in Kathmandu. Microbiol Insights. 2023;16:11786361231183675. doi:10.1177/11786361231183675
   Google Scholar
• Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020;29(3):654–669. doi:10.1002/pro.3819
   PubMed Web of Science ®Google Scholar
• Vega F, Alarcón P, Domínguez M, et al. Aislamiento de Staphylococcus aureus hetero-resistente a vancomicina en Hospital Clínico Regional de Concepción, Chile. Revista chilena de infectología. 2015;32:588–590. doi:10.4067/S0716-10182015000600017
   PubMedGoogle Scholar
• Doménech Berrozpe J. Tratado general de Biofarmacia y Farmacocinética. Volumen II. Madrid: Síntesis; 2013.
   Google Scholar
• Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–1153. doi:10.1007/s00134-020-06050-1
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(Suppl. 1):S35–S39. doi:10.1086/491712
   PubMedGoogle Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925–942. doi:10.2165/00003088-200443130-00005
   PubMed Web of Science ®Google Scholar
• Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666–675. doi:10.1093/cid/ciu398
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Toiviainen T, De Bruin ML, Meulendijks D. Pharmacogenetic-pharmacokinetic interactions in drug marketing authorization applications via the European Medicines Agency between 2014 and 2017. Clin Pharmacol Ther. 2020;108(2):338–349. doi:10.1002/cpt.1834
   PubMed Web of Science ®Google Scholar
• Póvoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. Eur Respir J. 2005;25(5):804–812. doi:10.1183/09031936.05.00071704
   PubMed Web of Science ®Google Scholar
• Martins EC, Silveira LDF, Viegas K, et al. Neutrophil-lymphocyte ratio in the early diagnosis of sepsis in an intensive care unit: a case-control study. Rev Bras Ter Intensiva. 2019;31(1):64–70. doi:10.5935/0103-507x.20190010
   PubMedGoogle Scholar
• Filipsen N, Bro H, Bjerrum L, Jensen JS, Aabenhus R. The Procalcitonin-guided Antibiotics in Respiratory Infections (PARI) project in general practice - a study protocol. BMC Prim Care. 2022;23(1):43. doi:10.1186/s12875-022-01646-6
   PubMedGoogle Scholar
• Mauliņa I, Darbiniece K, Miķelsone-Jansone L, Erts R, Bandere D, Krūmiņa A. Experience of vancomycin therapeutic drug monitoring in two multidisciplinary hospitals in Latvia. Medicina (Kaunas). 2022;58(3):370. doi:10.3390/medicina58030370
   PubMed Web of Science ®Google Scholar
• Phillips CJ, Wisdom AJ, McKinnon RA, Woodman RJ, Gordon DL. Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis. Infect Drug Resist. 2018;11:2081–2094. doi:10.2147/idr.S176519
   PubMed Web of Science ®Google Scholar
• Setiawan E, Cotta MO, Roberts JA, Abdul-Aziz MH. A systematic review on antimicrobial pharmacokinetic differences between asian and non-asian adult populations. Antibiotics (Basel). 2023;12(5):803. doi:10.3390/antibiotics12050803
   PubMed Web of Science ®Google Scholar
• Yousif ZK, Koola JD, Macedo E, et al. Clinical characteristics and outcomes of drug-induced acute kidney injury cases. Kidney Int Rep. 2023;8(11):2333–2344. doi:10.1016/j.ekir.2023.07.037
   PubMed Web of Science ®Google Scholar
• Avedissian SN, Pais G, Liu J, et al. The pharmacodynamic-toxicodynamic relationship of AUC and C(max) in vancomycin-induced kidney injury in an animal model. Antimicrob Agents Chemother. 2021;65(3). doi:10.1128/aac.01945-20
   Web of Science ®Google Scholar
• Katip W, Okonogi S, Oberdorfer P. The thirty-day mortality rate and nephrotoxicity associated with trough serum vancomycin concentrations during treatment of enterococcal infections: a propensity score matching analysis. Front Pharmacol. 2021;12:773994. doi:10.3389/fphar.2021.773994
   PubMed Web of Science ®Google Scholar
• Lu R, Ren J, Zhou X, Zheng B, Peng F. Risk factors for acute kidney injury associated with intravenous vancomycin in neurosurgical inpatients: a retrospective study. Eur J Clin Pharmacol. 2023;80(1):65–73. doi:10.1007/s00228-023-03581-6
   PubMed Web of Science ®Google Scholar
• Tsutsuura M, Moriyama H, Kojima N, et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis. 2021;21(1):153. doi:10.1186/s12879-021-05858-6
   PubMed Web of Science ®Google Scholar
• Sinha Ray A, Haikal A, Hammoud KA, Yu ASL. Vancomycin and the risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016;11(12):2132–2140. doi:10.2215/cjn.05920616
   PubMed Web of Science ®Google Scholar
• Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of Vancomycin. Clin Pharmacol Ther. 2017;102(3):459–469. doi:10.1002/cpt.726
   PubMed Web of Science ®Google Scholar
• Chen TT, Liu MP, Sun HC. Evaluation of therapeutic vancomycin monitoring in Taiwan. Microbiol Spectr. 2022;10(2):e0156221. doi:10.1128/spectrum.01562-21
   PubMed Web of Science ®Google Scholar
• Komoto A, Maiguma T, Teshima D, Sugiyama T, Haruki Y. Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to methicillin-resistant Staphylococcus aureus. PLOS ONE. 2018;13(9):e0203453. doi:10.1371/journal.pone.0203453
   PubMed Web of Science ®Google Scholar
• Se CF, Da VR, Pa CC, Gc FT. Aminoglycosides' dosage in hematological malignancies and febrile neutropenia: extended interval or conventional dosage? Per Med. 2023;20(1):5–11. doi:10.2217/pme-2022-0068
   PubMed Web of Science ®Google Scholar
• Admas T, Banjaw A. Healthcare professionals' knowledge, attitudes and future expectations towards personalized medicine. Per Med. 2021;18(5):483–490. doi:10.2217/pme-2020-0185
   PubMedGoogle Scholar
• Duricova J, Jadrnickova P, Brozmanova H, Kacirova I. Therapeutic drug monitoring guided fluconazole therapy in a patient with cholangitis sepsis. Per Med. 2022;19(1):9–14. doi:10.2217/pme-2021-0010
   PubMed Web of Science ®Google Scholar